A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab

Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology, 19(33), 2213–2225. https://doi.org/10.2217/fon-2023-0284
Authors:
Alexander Spira
Nicolas Girard
Matthew Krebs
Keunchil Park
Catherine Shu
Lindsay Dougherty
Byoung Chul Cho
Affiliated Authors:
Catherine Shu
Columbia Affiliation:
Subjects:
Advancements in Lung Cancer Research (OpenAlex Topic)
Diagnosis and Treatment of Lung Cancer (OpenAlex Topic)
RNA Methylation and Modification in Gene Expression (OpenAlex Topic)
Carcinoma, Non-Small-Cell Lung (MeSH)
ErbB Receptors (MeSH)
Exons (MeSH)
Lung Neoplasms (MeSH)
Author Keywords:
clinical trials
lung
metastasis
novel therapy
elink
Publication Type:
Article
Unique ID:
10.2217/fon-2023-0284
PMID:
39189517
DOI:
10.2217/fon-2023-0284
Journal:
Future Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View OpenAlex Record

Record Created: